These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 32972243)
1. Pharmacological properties and biochemical mechanisms of μ-opioid receptor ligands might be due to different binding poses: MD studies. Ronsisvalle S; Panarello F; Spadaro A; Franchini S; Pappalardo M; Guccione S; Basile L Future Med Chem; 2020 Nov; 12(22):2001-2018. PubMed ID: 32972243 [No Abstract] [Full Text] [Related]
2. Computational insights into the molecular mechanisms of differentiated allosteric modulation at the mu opioid receptor by structurally similar bitopic modulators. Wang H; Reinecke BA; Zhang Y J Comput Aided Mol Des; 2020 Aug; 34(8):879-895. PubMed ID: 32193867 [TBL] [Abstract][Full Text] [Related]
3. An LP1 analogue, selective MOR agonist with a peculiar pharmacological profile, used to scrutiny the ligand binding domain. Ronsisvalle S; Aricò G; Panarello F; Spadaro A; Pasquinucci L; Pappalardo MS; Parenti C; Ronsisvalle N Bioorg Med Chem; 2016 Nov; 24(21):5280-5290. PubMed ID: 27624520 [TBL] [Abstract][Full Text] [Related]
11. Structure-Activity Relationship Studies of 6α- and 6β-Indolylacetamidonaltrexamine Derivatives as Bitopic Mu Opioid Receptor Modulators and Elaboration of the "Message-Address Concept" To Comprehend Their Functional Conversion. Obeng S; Wang H; Jali A; Stevens DL; Akbarali HI; Dewey WL; Selley DE; Zhang Y ACS Chem Neurosci; 2019 Mar; 10(3):1075-1090. PubMed ID: 30156823 [TBL] [Abstract][Full Text] [Related]
12. Mixed κ/μ partial opioid agonists as potential treatments for cocaine dependence. Bidlack JM Adv Pharmacol; 2014; 69():387-418. PubMed ID: 24484983 [TBL] [Abstract][Full Text] [Related]
13. Bioactivity of new mu and delta opioid peptides. Capasso A Med Chem; 2007 Sep; 3(5):480-7. PubMed ID: 17897075 [TBL] [Abstract][Full Text] [Related]
14. The antinociceptive properties of endomorphin-1 and endomorphin-2 in the mouse. Tseng LF Jpn J Pharmacol; 2002 Jul; 89(3):216-20. PubMed ID: 12184724 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of N-substituent structural variations in opioid receptor profile of LP1. Pasquinucci L; Turnaturi R; Aricò G; Parenti C; Pallaki P; Georgoussi Z; Ronsisvalle S Bioorg Med Chem; 2016 Jun; 24(12):2832-42. PubMed ID: 27234885 [TBL] [Abstract][Full Text] [Related]
16. Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence. Wang D; Raehal KM; Bilsky EJ; Sadée W J Neurochem; 2001 Jun; 77(6):1590-600. PubMed ID: 11413242 [TBL] [Abstract][Full Text] [Related]
18. The benzomorphan-based LP1 ligand is a suitable MOR/DOR agonist for chronic pain treatment. Pasquinucci L; Parenti C; Turnaturi R; Aricò G; Marrazzo A; Prezzavento O; Ronsisvalle S; Georgoussi Z; Fourla DD; Scoto GM; Ronsisvalle G Life Sci; 2012 Jan; 90(1-2):66-70. PubMed ID: 22100511 [TBL] [Abstract][Full Text] [Related]
19. Ligand interaction, binding site and G protein activation of the mu opioid receptor. Cui X; Yeliseev A; Liu R Eur J Pharmacol; 2013 Feb; 702(1-3):309-15. PubMed ID: 23415745 [TBL] [Abstract][Full Text] [Related]
20. Molecular insights into the biased signaling mechanism of the μ-opioid receptor. Cong X; Maurel D; Déméné H; Vasiliauskaité-Brooks I; Hagelberger J; Peysson F; Saint-Paul J; Golebiowski J; Granier S; Sounier R Mol Cell; 2021 Oct; 81(20):4165-4175.e6. PubMed ID: 34433090 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]